Active ingredient
- burosumab
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PLGB 50262/0003.
Crysvita (burosumab)
Package leaflet: Information for the user
CRYSVITA 10 mg solution for injection
CRYSVITA 20 mg solution for injection
CRYSVITA 30 mg solution for injection
burosumab
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
What is in this leaflet
1. What CRYSVITA is and what it is used for
2. What you need to know before you use CRYSVITA
3. How to use CRYSVITA
4. Possible side effects
5. How to store CRYSVITA
6. Contents of the pack and other information
1. What CRYSVITA is and what it is used for
What CRYSVITA is
CRYSVITA contains the active substance burosumab. This is a type of medicine called a human monoclonal antibody.
What is CRYSVITA used for
CRYSVITA is used to treat X-linked hypophosphataemia (XLH). It is used in children and adolescents aged 1 to 17 years, and in adults.
What is X-Linked Hypophosphataemia (XLH)
X-Linked Hypophosphataemia (XLH) is a genetic disease.
How CRYSVITA works
CRYSVITA attaches to FGF23 in the blood which stops FGF23 from working and increases the phosphate levels in the blood so that normal levels of phosphate can be achieved.
2. What you need to know before you use CRYSVITA
Do not use CRYSVITA if
Allergic reactions
Stop taking CRYSVITA and contact your doctor straight away if you have any of the following side effects, as they could be signs of an allergic reaction:
Do not take CRYSVITA if any of the above apply to you. If you are not sure, talk to your doctor before using CRYSVITA.
Warnings and precautions
Skin reactions
You may get skin reactions where the injection is given, see section 4 for more information. If these reactions are severe, tell your doctor.
Tests and checks
Your doctor will check the phosphate and calcium levels in your blood and urine and may also do a renal ultrasound during your treatment in order to reduce the risk of hyperphosphataemia (too much phosphate in the blood) and ectopic mineralisation (a build-up of calcium in tissues such as the kidneys). Your serum parathyroid hormone level will also be checked from time to time.
Children under 1 year
CRYSVITA should not be given to children under 1 year of age because the safety and effects of the medicine have not been studied in this age group.
Other medicines and CRYSVITA
Tell your doctor if you are taking, have recently taken, or might take any other medicines.
Do not take CRYSVITA and tell your doctor if you are taking:
Talk to your doctor before taking CRYSVITA if you are taking:
Pregnancy and breastfeeding
If you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. This is because it is not known if CRYSVITA will affect the baby.
CRYSVITA is not recommended in pregnancy.
If you could get pregnant, you must use an effective method of contraception (birth control) while using CRYSVITA. You should discuss this with your doctor.
It is not known if CRYSVITA passes into breast milk, and a risk to newborns or infants cannot be ruled out. You should discuss this with your doctor.
Driving, riding a bike and using machines
It is possible that CRYSVITA could cause dizziness and affect you being able to ride a bike, use any tools or machines or to drive. If you think you are affected, do not ride a bike, use any tools or machines or drive, and tell your doctor.
CRYSVITA contains sorbitol
This medicine contains 45.91 mg of sorbitol in each vial which is equivalent to 45.91 mg/ml.
3. How to use CRYSVITA
CRYSVITA should be given by injection under the skin (subcutaneous use) in the upper arm, abdomen, buttock or thigh. This medicine will be given to you or your child by a healthcare provider. Alternatively, your doctor may recommend that you inject yourself or your child. A healthcare provider will show you how to do this. The first self-injection after start of treatment or after any dose change should be carried out in front of them. A detailed ‘Instructions for Use’ section is provided at the end of this leaflet. Always follow these instructions carefully when giving yourself or your child the CRYSVITA injection.
Always use this medicine exactly as your doctor, nurse or pharmacist has told you. Check with your doctor, nurse or pharmacist if you are not sure.
How much CRYSVITA you will need
The dose is based on your body weight. Your doctor will work out the right dose for you.
Your CRYSVITA dose will need to be injected:
Your doctor will perform checks to make sure that you are getting the right dose and may change your dose if needed.
The maximum dose you will be given is 90 mg.
If you have been given more CRYSVITA than you should
If you think that you have been given too much CRYSVITA, tell your doctor straight away.
If you miss a dose of CRYSVITA
If a dose is missed, talk to your doctor straight away. The missed dose should be given as soon as possible and your doctor will re-arrange future doses accordingly.
If you have any further questions on the use of this medicine, ask your doctor.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects in children and adolescents
Very common (may affect more than 1 in 10 children and adolescents)
Common (may affect up to 1 in 10 children and adolescents)
Not known (frequency cannot be estimated from the available data)
Side effects in adults
Very common (may affect more than 1 in 10 adults)
Common (may affect up to 1 in 10 adults)
Reporting of side effects
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
5. How to store CRYSVITA
Keep CRYSVITA out of the sight and reach of children.
Do not use CRYSVITA after the expiry date which is stated on the carton and label.
Store in a refrigerator (2°C to 8°C). Do not freeze.
Keep the vial in the outer carton in order to protect from light.
Do not use CRYSVITA if it contains visible particles.
Do not throw away any medicines via wastewater or household waste. These measures will help protect the environment.
If self-injecting, see step 5 of the ‘Instructions for Use’ in the end of the Package Leaflet for instructions on disposal of unused medicines and supplies.
If you have questions on how to throw away medicines you no longer use, ask your healthcare provider or pharmacist.
6. Contents of the pack and other information
What CRYSVITA contains
The active substance is burosumab. Each vial contains either 10, 20 or 30 mg of burosumab.
The other ingredients are L-histidine, D-sorbitol (E420), polysorbate 80, L-methionine, 10%, hydrochloric acid, and water for injections. (See “CRYSVITA contains sorbitol” in section 2 for more information).
What CRYSVITA looks like and contents of the pack
CRYSVITA comes as a clear to slightly opalescent, colourless to pale yellow/brown solution for injection in a small glass vial. Each pack contains 1 vial.
Marketing Authorisation Holder
Manufacturer
This leaflet was last revised in February 2022
This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.
INSTRUCTIONS FOR USE
Read these Instructions for Use carefully before you use CRYSVITA:
Step 1. Gather and Inspect Supplies
Remove the CRYSVITA vials you need from the refrigerator.
Check the strength on the label of each vial.
Make sure that you have the correct number of vials to match the dose in mg as advised by your healthcare provider.
If you are not sure, ask your healthcare provider for advice.
Let the vials warm to room temperature for 30 minutes. Do not warm the vials in any other way, such as with hot water or a microwave oven. Do not put the vials in direct sunlight.
Check the expiry date (shown after EXP) on the label of the vial.
Inspect the liquid in the vial. Do not shake.
Do not use the vial if it is:
Place all the items you will need on a clean, flat surface. For each injection you will need:
A. Vial(s) of CRYSVITA for injection
B. One syringe with plunger
C. One large syringe needle to withdraw CRYSVITA
D. One small syringe needle to inject CRYSVITA
E. Alcohol wipes
F. Sharps container
G. Plaster (if required)
H. Gauze pad or cotton wool
Contact your healthcare provider if you do not have these supplies.
Your healthcare provider will explain the use of different needles.
The large needle is used for withdrawing CRYSVITA from the vial.
The small needle is used for injecting CRYSVITA.
If you are not sure, ask your healthcare provider for advice before use.
Do not use any items that have missing pieces or are damaged in any way.
Do not remove the caps from the needles until you are ready to use them.
Wash your hands thoroughly with soap and water before going to Step 2.
STEP 2. Withdraw CRYSVITA and Prepare Injection
Remove the sealing cap from the vial to reveal the rubber stopper.
Clean the rubber stopper with an alcohol wipe and let it dry. Don’t touch the rubber stopper after cleaning it.
Select the large needle and remove from the sterile packaging but do not remove the cap covering the needle.
To attach the needle to the syringe, hold the large needle by the protective cap in one hand and the syringe by the barrel in the other hand.
Depending on the supplies you have been given;
Do not touch the needle itself or the end of the syringe where the needle attaches.
Once the needle is firmly attached, hold the syringe by the barrel with the needle pointing up.
Remove the needle cap by pulling it straight off.
Do not throw the needle cap away.
Do not touch the needle or allow the needle to touch any surface once the cap has been removed.
Do not use the syringe if you drop it after removing the cap or if the needle appears damaged.
Your healthcare provider will tell you how much liquid you need to inject. This will normally be 1ml for each injection. Your healthcare provider will show you which mark to use if you need to inject less than 1ml.
Always use the mark equal to your dose. If you are not sure, ask your healthcare provider for advice before use.
Pull back the syringe plunger until the end of the plunger lines up with mark equal to your dose. This fills the syringe with air.
Keep the vial on a flat surface.
Slowly insert the large needle through the rubber stopper and into the vial.
Do not let the tip of the needle touch the liquid in the vial.
If the tip of the needle touches the liquid, slowly pull the needle until it no longer touches the liquid.
Slowly push the plunger into the syringe.
This pushes air from the syringe into the vial.
Keep the needle in the vial and turn the vial upside down.
Make sure the tip of the needle is at the bottom of the liquid.
Slowly pull back the plunger to fill the syringe until the end of the plunger lines up with the mark equal to your dose.
Keep the tip of the needle in the liquid at all times.
Check the liquid in the syringe for air bubbles.
If you see bubbles,
Check your dose again against the markings on the syringe.
If required, withdraw some more liquid to line up with the mark equal to your dose.
Check again for bubbles and repeat the process if required.
When there are no bubbles in the syringe, pull the syringe and needle straight down out of the vial.
Remove the large needle from the syringe.
Select the small needle and remove from the sterile packaging but do not remove the cap covering the needle.
To attach the needle to the syringe, hold the small needle by the protective cap in one hand and the syringe by the barrel in the other hand.
Depending on the supplies you have been given,
Do not touch the needle itself or the end of the syringe where the needle attaches.
Step 3. Prepare the Injection Site
The injection must be given into the fatty layer just below the skin. You will need to choose an injection site. If you are giving the injection to yourself, suitable areas are:
If you are giving the injection to someone else, suitable areas are:
Do not inject:
If you are giving more than one injection, use a different site for each injection. Clean each injection site with a new alcohol wipe and leave the skin to dry.
CRYSVITA should be injected into clean dry skin.
Step 4. Inject CRYSVITA
Remove the small needle cap by pulling it straight off.
Pinch the skin firmly between your thumb and fingers, creating an area about 5 cm wide.
Hold the syringe between the thumb and index finger of your dominant hand.
The needle should be inserted into the skin at a 45° angle or 90° angle.
Your healthcare provider will show you which angle you should use.
Use a quick ‘dart-like’ motion to insert the needle into the pinched skin.
Do not push the plunger when inserting the needle.
When the needle is inserted do not move it around.
Keep pinching the skin.
Slowly push the plunger into the syringe, for up to 30 seconds, until the syringe is empty.
After you have given the full dose, remove the injection by gently pulling the syringe straight out.
Release the pinched skin.
Press the injection site with a cotton ball or gauze pad for a few seconds to stop bleeding. Apply a plaster if needed.
Do not rub the injection site.
To avoid any injury, do not put the cap back on the small needle. Place the uncapped needle in the sharps disposal container.
Step 5. After each injection
Put your used needles and caps, syringes and vials in the sharps disposal container.
Do not throw away needles, syringes or vials in your household waste.
Do not save vials with leftover medicine for future use or pass it on to others.
When your sharps container is almost full, you will need to follow your local guidelines to request another container and to dispose of it correctly.
Reminder: If you are giving more than one injection, repeat steps 2-5 for each injection.
Use new supplies for each injection.
Note the date of the injection and all the areas where you have injected so that you use different sites for the next injection.
A video showing you how to prepare and give the injection is available on the following link: www.myinject.eu
+ 44 (0)1896 664 000